Friday, October 16, 2026

Retail

10 articles

Steak and Ale revival faces 70% failure risk in pattern mirroring global dormant brand collapses

Steak and Ale revival faces 70% failure risk in pattern mirroring global dormant brand collapses

Steak and Ale's 2024 reopening confronts a 70% failure probability after 16 years of closure, facing challenges that bankrupted dormant brand revivals from Howard Johnson's in the US to Wimpy in the UK. The casual dining chain must compete against entrenched rivals while targeting consumers with no memory of its pre-2008 operations across 280 locations.

ViaNews Editorial Team•
Carrefour and JCDecaux deploy retail media network across 179 Spanish sites in 2027 expansion

Carrefour and JCDecaux deploy retail media network across 179 Spanish sites in 2027 expansion

Carrefour, Carmila, Unlimitail, and JCDecaux will launch a retail media network across 179 Spanish locations in January 2027, extending their French model to Spain. The partnership combines JCDecaux's outdoor advertising reach with Carrefour's customer data across 91 shopping centres and 88 outdoor sites. Spain's 575 shopping centres attract 2.4 billion annual visitors, offering immediate scale for the joint venture.

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com